[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" hide_on_mobile="small-visibility,medium-visibility,large-visibility" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" border_style="solid"][fusion_builder_row][fusion_builder_column type="1_1" type="1_1" background_position="left top" border_style="solid" border_position="all" spacing="yes" background_repeat="no-repeat" margin_top="0px" margin_bottom="0px" animation_speed="0.3" animation_direction="left" hide_on_mobile="small-visibility,medium-visibility,large-visibility" center_content="no" last="no" hover_type="none" min_height="" link=""][fusion_text]

Guardant Health, Inc. V. Natera, Inc.

Case Background

On May 27, 2022, Plaintiff Guardant Health, Inc. filed a false advertising lawsuit in the United States District Court, Northern District of California (Case number: 3:21cv4062). This case was assigned to Judge Edward M. Chen and referred to Magistrate Judge Sallie Kim.

Cause

Guardant Health filed a lawsuit against Natera, Inc. over false advertising claims regarding cancer diagnostic tests. The dispute centered on liquid biopsy tests for detecting colorectal cancer (CRC) recurrence – Guardant's Reveal test versus Natera's Signatera test. Natera launched an advertising campaign that made false comparisons between the two tests, claiming that Signatera was superior in sensitivity, failure rate, and negative predictive value. The campaign coincided with Reveal's launch and targeted oncologis